Praxis Precision Medicines, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 09/30/24 | FY 06/30/24 | FY 03/31/24 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $8.6M | — | — | — |
| Research and development | $267.1M | $152.4M | — | — | — |
| Operating expenses | $326.2M | $208.7M | — | — | — |
| Operating income | -$326.2M | -$200.2M | — | — | — |
| Pretax income | -$302.8M | -$182.7M | — | — | — |
| Income tax expense | $471,000 | $76,000 | — | — | — |
| Net income | -$303.3M | -$182.8M | — | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $357.3M | $215.4M | — | — | — |
| Current assets | $610.9M | $404.4M | — | — | — |
| Total assets | $937.9M | $483.1M | — | — | — |
| Current liabilities | $59.8M | $37.5M | — | — | — |
| Total liabilities | $59.8M | $37.7M | — | — | — |
| Stockholders' equity | $878.1M | $445.4M | $382.7M | $419.1M | $229.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$249.1M | -$131.8M | — | — | — |
| Depreciation and amortization | $140,000 | $358,000 | — | — | — |
| Stock-based compensation | $33.9M | $41.4M | — | — | — |
| Capital expenditure | $56,000 | $0 | — | — | — |
| Free cash flow | -$249.1M | -$131.8M | — | — | — |
| Impairments | $0 | $0 | — | — | — |
Shares outstanding 27.9M · Free float 61.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.